Discovery and history

• What tirzepatide is and how the dual GIP/GLP-1 design works
• How the SURPASS and SURMOUNT trials read, tier by tier
• Where the emerging uses (OSA, MASH, heart) actually stand
• How to think critically about dosing, safety, and access claims

1. 01 Discovery and history The first dual incretin: how tirzepatide arrived free
2. 02 Chemistry and structure How a 39-residue peptide was engineered to last a week paid
3. 03 Dual GIP and GLP-1 mechanism Two receptors, one metabolic reset paid
4. 04 Metabolic and body-composition effects What changes in the body, beyond the number on the scale paid
5. 05 Clinical trials: the SURPASS program How tirzepatide was tested in type 2 diabetes paid
6. 06 Clinical trials: the SURMOUNT program The obesity trials that made the headlines paid
7. 07 Emerging applications Sleep apnea, fatty liver, and the heart paid
8. 08 Tirzepatide versus other agents Where it leads, where it trails, and what comes next paid
9. 09 Dosing and Administration How tirzepatide is dosed, for education only paid
10. 10 Safety and side effects What can go wrong, and how likely it is paid
11. 11 Regulatory status and access Approvals, the compounding story, and getting the real thing paid
12. 12 Final Exam and Certification Pass the final exam to earn your certificate of completion. Exam

Strip away the headlines and tirzepatide is one engineered peptide with a single, unusual trick: it activates two gut-hormone receptors rather than one. That dual action is the whole reason it stands apart from earlier drugs in the same family.

It is given as a once-weekly injection under the skin. Beyond diabetes and obesity, it became the first medication the FDA approved for obstructive sleep apnea, a striking sign of how far its metabolic effects reach.

From first human dosing to four separate FDA-approved uses, tirzepatide moved unusually fast. The major beats show how quickly the evidence and the indications piled up.

What stands out is the compression of the whole arc: the gap between the first human data and a second, third and fourth approved use was only a handful of years. The underlying science and the commercial rollout moved almost in lockstep, which is unusual for a brand-new drug class.

To understand tirzepatide you first need the two natural signals it imitates. Both are incretins, gut hormones your intestine releases after a meal to prime the pancreas for the incoming glucose.

Drugs like semaglutide copy only GLP-1. Tirzepatide copies both GIP and GLP-1 at once, and that single design choice is the thread that everything else in this course builds on, from the chemistry to the trial results to the safety picture.

A few figures frame the scale of the effect and the molecule itself. They are worth anchoring early, because the rest of the course explains where each one comes from and how solid it is.

The numbers rise steadily with dose, which is a recurring pattern for tirzepatide. Higher doses do more, and in the pooled Zepbound weight-reduction trials severe gastrointestinal reactions also rose with dose, as the safety unit shows.

Before the deep dive, an honest map of what is genuinely proven versus merely promising. Tirzepatide has unusually strong trial evidence for its core uses, but the edges are softer than the marketing suggests.

Holding those tiers apart is the core skill this course builds. The weight and glucose story is genuinely strong; the heart and long-term stories are still being written.